Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy

• Published in: BMC cancer Vol. 24; no. 1; pp. 789 - 12
• Main Authors: Peng, Jing, Lin, Yanping, Sheng, Xiaonan, Yuan, Chenwei, Wang, Yan, Yin, Wenjin, Zhou, Liheng, Lu, Jinsong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.07.2024; BioMed Central; BMC
• Subjects: Adjuvant treatment; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Breast cancer; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer; Cancer patients; Care and treatment; Cell proliferation; Chemotherapy; Drug therapy; Female; Gene Expression Regulation, Neoplastic; Glycolysis; Health aspects; Humans; Identification and classification; Medical prognosis; Medical research; Medicine, Experimental; Metabolism; Methods; MicroRNA; MicroRNAs; MicroRNAs - blood; Middle Aged; miRNA; miRNA-1; Multivariate analysis; Neoadjuvant chemotherapy; Neoadjuvant therapy; Neoadjuvant Therapy - methods; Patients; Prognosis; Regression analysis; Serum biomarker; Signal transduction; Treatment Outcome; Tumor markers; Tumor suppressor genes; China; Canada; Neoadjuvant chemotherapy; miRNA-1; Breast cancer; Serum biomarker
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-12500-6

MicroRNA-1 (miR-1) is a tumour suppressor that can inhibit cell proliferation and invasion in several cancer types. In addition, miR-1 was found to be associated with drug sensitivity. Circulating miRNAs have been proven to be potential biomarkers with predictive and prognostic value. However, studies of miR-1 expression in the serum of breast cancer (BC) patients are relatively scarce, especially in patients receiving neoadjuvant chemotherapy (NAC). Serum samples from 80 patients were collected before chemotherapy, and RT-PCR was performed to detect the serum expression of miR-1. The correlation between miR-1 expression in serum and clinicopathological factors, including pathological complete response (pCR), was analyzed by the chi-squared test and logistic regression. KEGG and GSEA analysis were also performed to determine the biological processes and signalling pathways involved. The miR-1 high group included more patients who achieved a pCR than did the miR-1 low group (p < 0.001). Higher serum miR-1 levels showed a strong correlation with decreased ER (R = 0.368, p < 0.001) and PR (R = 0.238, p = 0.033) levels. The univariate model of miR-1 for predicting pCR achieved an AUC of 0.705 according to the ROC curve. According to the interaction analysis, miR-1 interacted with Ki67 to predict the NAC response. According to the Kaplan-Meier plot, a high serum miR-1 level was related to better disease-free survival (DFS) in the NAC cohort. KEGG analysis and GSEA results indicated that miR-1 may be related to the PPAR signalling pathway and glycolysis. In summary, our data suggested that miR-1 could be a potential biomarker for pCR and survival outcomes in patients with BC treated with NAC.